<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567446</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A02010-53</org_study_id>
    <secondary_id>2019/2619</secondary_id>
    <nct_id>NCT04567446</nct_id>
  </id_info>
  <brief_title>Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach</brief_title>
  <acronym>ONCOBIOTICS</acronym>
  <official_title>Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric prospective study with collection of biological samples as part of type II&#xD;
      research&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To define metagenomic signatures associated with cancer</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Define metagenomic signatures associated with the effectiveness of anticancer therapies</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>objective response rate, progression free survival</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patients who will start cancer treatment</arm_group_label>
    <description>Collection of biological samples (stool, blood, saliva) and data from patients included in the study will be performed:&#xD;
By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).&#xD;
Collection of biological resources (all samples will be collected in fresh):&#xD;
Stool: collected at diagnosis, before initiating anticancer treatment, during treatment&#xD;
Blood: 40 mL collection before, 3 and 6 months of treatment cancer&#xD;
Saliva: 5 mL collection before initiation of treatment cancer&#xD;
Collection of clinical data corresponding to each patient included in the study by a clinical research assistant</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool</intervention_name>
    <description>collection at diagnosis, before initiating anticancer treatment, during treatment</description>
    <arm_group_label>Patients who will start cancer treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>40 mL collection before, 3 and 6 months of treatment cancer</description>
    <arm_group_label>Patients who will start cancer treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saliva</intervention_name>
    <description>5 mL collection before initiation of treatment cancer</description>
    <arm_group_label>Patients who will start cancer treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with cancer who will start treatment anticancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with cancer who will start treatment anticancer (see cohorts).&#xD;
&#xD;
          -  Patient information and signature of the consent form before any specific procedure&#xD;
             for the study. The patient must be able and must be inclined to cooperate in the study&#xD;
             procedures.&#xD;
&#xD;
          -  Patient affiliated to a social security scheme or beneficiary of a similar scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Patient under guardianship or curatorship or deprived of liberty by a decision&#xD;
             judicial or administrative or patient unable to give his consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Zitvogel, MD,PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>laurence.zitvogel@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Derosa, MD</last_name>
    <email>deros.lisa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MÃ©lodie Bonvalet</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>melodie.bonvalet@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

